Altis Labs secures $6M in seed funding to develop AI imaging technology for clinical trials

　　Altis Labs, a company that develops artificial intelligence computational imaging technology to speed clinical trials, has raised $6 million in seed funding to further develop its technology.

　　The funds will be used to advance the company's Nota platform, which applies artificial intelligence imaging biomarker technology to solid tumor types and other therapeutic areas, the company said in a June 21 press release. Altis said drugmakers such as Bayer are already using the platform to analyze imaging data from Phase 1-3 clinical trials.

　　Computational imaging is a process that uses algorithms that rely on large amounts of calculations to indirectly form images through measurements.

　　Benchstrength (formerly part of General Catalyst) and Debiopharm Innovation Fund co-led the round. Other participants include former Verana Health CEO Doug Foster and Richard Gliklich, founder and CEO of data company OM1.

　　Felix Baldauf-Lenschen, co-founder and CEO of Altis, said in the release: "This partnership will help us reduce the excessive time and cost required to bring novel, effective treatments to patients in need. "

　　The Nota platform analyzes clinical trial imaging data and generates model predictions to provide researchers with a more accurate baseline snapshot of patients and measure the effectiveness of treatment in different subpopulations. The aim is to gain higher quality insights earlier in clinical development, thereby increasing the chances of success in later-stage trials. Altis said the data can also help developers make critical R&D decisions earlier and inform trial design, reimbursement strategies and reactivation of shelved therapies.

References:

1. Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials. https://www.fiercebiotech.com/cro/altis-labs-reels-6m-seed-funding-ai-imaging-used-clinical-trials